MX2010004252A - Combinacion que comprende derivados de purina y otros compuestos y el uso de los mismos para el tratamiento de enfermedades de vias respiratorias inflamatorias y obstructivas. - Google Patents
Combinacion que comprende derivados de purina y otros compuestos y el uso de los mismos para el tratamiento de enfermedades de vias respiratorias inflamatorias y obstructivas.Info
- Publication number
- MX2010004252A MX2010004252A MX2010004252A MX2010004252A MX2010004252A MX 2010004252 A MX2010004252 A MX 2010004252A MX 2010004252 A MX2010004252 A MX 2010004252A MX 2010004252 A MX2010004252 A MX 2010004252A MX 2010004252 A MX2010004252 A MX 2010004252A
- Authority
- MX
- Mexico
- Prior art keywords
- antagonist
- inhibitor
- component
- beta
- organic compounds
- Prior art date
Links
- 150000002894 organic compounds Chemical class 0.000 title 1
- 239000005557 antagonist Substances 0.000 abstract 3
- 239000000048 adrenergic agonist Substances 0.000 abstract 2
- 102000014974 beta2-adrenergic receptor activity proteins Human genes 0.000 abstract 2
- 108040006828 beta2-adrenergic receptor activity proteins Proteins 0.000 abstract 2
- 239000003149 muscarinic antagonist Substances 0.000 abstract 2
- 229940122086 Adenosine A2a receptor agonist Drugs 0.000 abstract 1
- 229940123169 Caspase inhibitor Drugs 0.000 abstract 1
- 229940126052 ENaC inhibitor Drugs 0.000 abstract 1
- 229940121948 Muscarinic receptor antagonist Drugs 0.000 abstract 1
- 208000027771 Obstructive airways disease Diseases 0.000 abstract 1
- 229940123932 Phosphodiesterase 4 inhibitor Drugs 0.000 abstract 1
- 229940122055 Serine protease inhibitor Drugs 0.000 abstract 1
- 101710102218 Serine protease inhibitor Proteins 0.000 abstract 1
- GUGOEEXESWIERI-UHFFFAOYSA-N Terfenadine Chemical compound C1=CC(C(C)(C)C)=CC=C1C(O)CCCN1CCC(C(O)(C=2C=CC=CC=2)C=2C=CC=CC=2)CC1 GUGOEEXESWIERI-UHFFFAOYSA-N 0.000 abstract 1
- 239000002465 adenosine A2a receptor agonist Substances 0.000 abstract 1
- 230000001387 anti-histamine Effects 0.000 abstract 1
- 239000000739 antihistaminic agent Substances 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 239000003246 corticosteroid Substances 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 239000002713 epithelial sodium channel blocking agent Substances 0.000 abstract 1
- 208000027866 inflammatory disease Diseases 0.000 abstract 1
- 230000002757 inflammatory effect Effects 0.000 abstract 1
- VNYSSYRCGWBHLG-AMOLWHMGSA-N leukotriene B4 Chemical compound CCCCC\C=C/C[C@@H](O)\C=C\C=C\C=C/[C@@H](O)CCCC(O)=O VNYSSYRCGWBHLG-AMOLWHMGSA-N 0.000 abstract 1
- YEESKJGWJFYOOK-IJHYULJSSA-N leukotriene D4 Chemical compound CCCCC\C=C/C\C=C/C=C/C=C/[C@H]([C@@H](O)CCCC(O)=O)SC[C@H](N)C(=O)NCC(O)=O YEESKJGWJFYOOK-IJHYULJSSA-N 0.000 abstract 1
- 239000002587 phosphodiesterase IV inhibitor Substances 0.000 abstract 1
- 239000003001 serine protease inhibitor Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
- A61K31/52—Purines, e.g. adenine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Pulmonology (AREA)
- Epidemiology (AREA)
- Rheumatology (AREA)
- Pain & Pain Management (AREA)
- Immunology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
Un medicamento que comprende, por separado o juntos: un componente (A) el cual es un agonista de receptor de adenosina A2A como se define en la especificaci?n; y un componente (B) el cual es uno o m?s compuestos seleccionados de: (i) un corticosteroide, (ii) un agonista de beta-2 adrenoceptor, (iii) un agente antimuscarnico, (iv) un antagonista de A2B, (v) una antihistamina, (Vi) un inhibidor de caspasa, (vii) un inhibidor de ENaC, (viii) un antagonista de LTB4, (ix) un antagonista de LTD4, (x) un inhibidor de serina proteasa, (xi) un inhibidor de PDE4 y (xii) un agonista de beta-2 adrenoceptor / antagonista muscar?nico de acci?n dual, para administraci?n simult?nea, secuencial o separada en el tratamiento de una enfermedad inflamatoria u obstructiva de v?as respiratorias.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP07118721 | 2007-10-17 | ||
| PCT/EP2008/063869 WO2009050198A2 (en) | 2007-10-17 | 2008-10-15 | Combination comprising purine derivatives and other compounds and the use thereof for the treatment of inflammatory and obstructive airway diseases |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2010004252A true MX2010004252A (es) | 2010-04-30 |
Family
ID=39185790
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2010004252A MX2010004252A (es) | 2007-10-17 | 2008-10-15 | Combinacion que comprende derivados de purina y otros compuestos y el uso de los mismos para el tratamiento de enfermedades de vias respiratorias inflamatorias y obstructivas. |
Country Status (21)
| Country | Link |
|---|---|
| US (1) | US20090181934A1 (es) |
| EP (1) | EP2211865A2 (es) |
| JP (1) | JP2011500630A (es) |
| KR (1) | KR20100075925A (es) |
| CN (1) | CN101827596A (es) |
| AR (1) | AR068879A1 (es) |
| AU (1) | AU2008313788A1 (es) |
| BR (1) | BRPI0818005A2 (es) |
| CA (1) | CA2702942A1 (es) |
| CL (1) | CL2008003057A1 (es) |
| CR (1) | CR11341A (es) |
| CU (1) | CU20100065A7 (es) |
| EA (1) | EA201000617A1 (es) |
| IL (1) | IL204723A0 (es) |
| MA (1) | MA31796B1 (es) |
| MX (1) | MX2010004252A (es) |
| PE (1) | PE20091392A1 (es) |
| TN (1) | TN2010000168A1 (es) |
| TW (1) | TW200927129A (es) |
| WO (1) | WO2009050198A2 (es) |
| ZA (1) | ZA201002336B (es) |
Families Citing this family (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GT200500281A (es) * | 2004-10-22 | 2006-04-24 | Novartis Ag | Compuestos organicos. |
| GB0500785D0 (en) | 2005-01-14 | 2005-02-23 | Novartis Ag | Organic compounds |
| RU2457209C2 (ru) * | 2006-04-21 | 2012-07-27 | Новартис Аг | Производные пурина, предназначенные для применения в качестве агонистов аденозинового рецептора а2а |
| GB0607950D0 (en) * | 2006-04-21 | 2006-05-31 | Novartis Ag | Organic compounds |
| GB0607945D0 (en) * | 2006-04-21 | 2006-05-31 | Novartis Ag | Organic compounds |
| GB0607953D0 (en) * | 2006-04-21 | 2006-05-31 | Novartis Ag | Organic compounds |
| GB0607948D0 (en) * | 2006-04-21 | 2006-05-31 | Novartis Ag | Organic compounds |
| GB0607944D0 (en) * | 2006-04-21 | 2006-05-31 | Novartis Ag | Organic compounds |
| EP1889846A1 (en) | 2006-07-13 | 2008-02-20 | Novartis AG | Purine derivatives as A2a agonists |
| EP1903044A1 (en) * | 2006-09-14 | 2008-03-26 | Novartis AG | Adenosine Derivatives as A2A Receptor Agonists |
| RU2009121819A (ru) * | 2006-11-10 | 2010-12-20 | Новартис АГ (CH) | Производные моноацетата циклопентендиола |
| KR20100068286A (ko) * | 2007-10-17 | 2010-06-22 | 노파르티스 아게 | 아데노신 ａ1 수용체 리간드로서의 퓨린 유도체 |
| ES2627541T3 (es) | 2012-04-20 | 2017-07-28 | Ucb Pharma, S.A. | Métodos para tratar la enfermedad de Parkinson |
| JOP20210164A1 (ar) | 2019-01-11 | 2023-01-30 | Omeros Corp | طرق وتركيبات علاج السرطان |
| WO2026006723A1 (en) * | 2024-06-27 | 2026-01-02 | Anand Rene | Reagents and methods for treating headache and migraine pain and co-morbidities thereof |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GT200500281A (es) * | 2004-10-22 | 2006-04-24 | Novartis Ag | Compuestos organicos. |
| GB0607945D0 (en) * | 2006-04-21 | 2006-05-31 | Novartis Ag | Organic compounds |
| GB0607950D0 (en) * | 2006-04-21 | 2006-05-31 | Novartis Ag | Organic compounds |
| RU2457209C2 (ru) * | 2006-04-21 | 2012-07-27 | Новартис Аг | Производные пурина, предназначенные для применения в качестве агонистов аденозинового рецептора а2а |
| GB0607953D0 (en) * | 2006-04-21 | 2006-05-31 | Novartis Ag | Organic compounds |
-
2008
- 2008-10-08 US US12/247,764 patent/US20090181934A1/en not_active Abandoned
- 2008-10-15 AR ARP080104494A patent/AR068879A1/es not_active Application Discontinuation
- 2008-10-15 EA EA201000617A patent/EA201000617A1/ru unknown
- 2008-10-15 CN CN200880112188A patent/CN101827596A/zh active Pending
- 2008-10-15 KR KR1020107008300A patent/KR20100075925A/ko not_active Withdrawn
- 2008-10-15 PE PE2008001774A patent/PE20091392A1/es not_active Application Discontinuation
- 2008-10-15 MX MX2010004252A patent/MX2010004252A/es not_active Application Discontinuation
- 2008-10-15 JP JP2010529369A patent/JP2011500630A/ja active Pending
- 2008-10-15 EP EP08838649A patent/EP2211865A2/en not_active Withdrawn
- 2008-10-15 BR BRPI0818005 patent/BRPI0818005A2/pt not_active IP Right Cessation
- 2008-10-15 CA CA2702942A patent/CA2702942A1/en not_active Abandoned
- 2008-10-15 AU AU2008313788A patent/AU2008313788A1/en not_active Abandoned
- 2008-10-15 WO PCT/EP2008/063869 patent/WO2009050198A2/en not_active Ceased
- 2008-10-16 CL CL2008003057A patent/CL2008003057A1/es unknown
- 2008-10-16 TW TW097139728A patent/TW200927129A/zh unknown
-
2010
- 2010-03-25 IL IL204723A patent/IL204723A0/en unknown
- 2010-03-26 CR CR11341A patent/CR11341A/es not_active Application Discontinuation
- 2010-04-01 ZA ZA2010/02336A patent/ZA201002336B/en unknown
- 2010-04-14 CU CU20100065A patent/CU20100065A7/es unknown
- 2010-04-16 TN TN2010000168A patent/TN2010000168A1/fr unknown
- 2010-04-30 MA MA32802A patent/MA31796B1/fr unknown
Also Published As
| Publication number | Publication date |
|---|---|
| TN2010000168A1 (en) | 2011-11-11 |
| CR11341A (es) | 2010-05-06 |
| AU2008313788A1 (en) | 2009-04-23 |
| CU20100065A7 (es) | 2011-10-05 |
| PE20091392A1 (es) | 2009-10-14 |
| EP2211865A2 (en) | 2010-08-04 |
| IL204723A0 (en) | 2010-11-30 |
| WO2009050198A3 (en) | 2009-09-11 |
| KR20100075925A (ko) | 2010-07-05 |
| CL2008003057A1 (es) | 2009-06-26 |
| ZA201002336B (en) | 2011-04-28 |
| CA2702942A1 (en) | 2009-04-23 |
| US20090181934A1 (en) | 2009-07-16 |
| AR068879A1 (es) | 2009-12-09 |
| CN101827596A (zh) | 2010-09-08 |
| EA201000617A1 (ru) | 2010-10-29 |
| BRPI0818005A2 (pt) | 2015-04-14 |
| WO2009050198A2 (en) | 2009-04-23 |
| JP2011500630A (ja) | 2011-01-06 |
| MA31796B1 (fr) | 2010-10-01 |
| TW200927129A (en) | 2009-07-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| TN2010000168A1 (en) | Organic compounds | |
| WO2009017838A3 (en) | Combinations of jak-2 inhibitors and other agents | |
| WO2007092936A3 (en) | Method to treat gastric lesions | |
| MA32049B1 (fr) | Traitement du cancer avec des combinaisons d'inhibiteurs de topoisomerase et d'inhibiteurs de parp | |
| WO2005049027A3 (en) | Combinations useful for the treatment of neuronal disorders | |
| MA30725B1 (fr) | Administration d'inhibiteurs de la dipeptidyl peptidase | |
| MX2009006401A (es) | Derivados de indazol como inhibidores de cinasa para el tratamiento del cancer. | |
| WO2008010921A3 (en) | Modulators of pharmacokinetic properties of therapeutics | |
| WO2007101224A3 (en) | Inhibitors of the unfolded protein response and methods for their use | |
| UA94129C2 (ru) | Соединения для ингибирования митоза | |
| WO2008057802A3 (en) | Compositions comprising at least one acid labile proton pump inhibiting agents, optionally other pharmaceutically active agents and methods of using same | |
| WO2007088489A3 (en) | Pharmaceutical composition containing a central opioid agonist, a central opioid antagonist, and a peripheral opioid antagonist, and method for making the same | |
| MX2010002584A (es) | Derivados de piperidina como agonistas de receptores muscarinicos. | |
| WO2008002514A3 (en) | Combination cough treatment compounds and method of treating common coughs | |
| GEP20125458B (en) | Matrix metalloproteinase inhibitors | |
| MX2007006066A (es) | Inhibidores de jnk para el tratamiento de lesiones del snc. | |
| UA99914C2 (ru) | Способ применения антагонистов вазопресина со средствами антрациклиновой химиотерапии для снижения кардиотоксичности | |
| EA201071395A1 (ru) | Ингибитор толерантности к анальгетику | |
| DE602007012313D1 (de) | Als a2b-adenosinrezeptorantagonisten geeignete 5-phenyl-6-pyridin-4-yl-1,3-dihydro-2h-imidazoä4,5-büpyridin-2-onderivate | |
| WO2006116733A3 (en) | Protein kinase inhibitors | |
| WO2007143163A3 (en) | Pharmaceutical compositions for sustained release of phenyephrine | |
| MX2009005798A (es) | Recuperacion de apoplejia. | |
| BRPI0617673C1 (pt) | composições de inibidores de fosfodiesterase do tipo iv | |
| WO2008075979A3 (en) | Tablet formulation | |
| WO2006128674A8 (en) | Combinations of indacaterol derivatives and other agents for the treatment of airway diseases |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA | Abandonment or withdrawal |